7.1 Radiation Oncology Principles & Toxicity Management

Radiation Oncology Principles & Toxicity Management

Radiation therapy (RT) is a localized antineoplastic treatment modality utilized in approximately 50% of all cancer patients as curative, adjuvant, neoadjuvant, or palliative therapy. Ionizing radiation causes cell death primarily by damaging cellular DNA, disrupting the molecular machinery required for cellular replication and survival. For Advanced Practice Registered Nurses (APRNs), managing radiation oncology patients requires a sophisticated understanding of radiation physics, radiobiology, delivery techniques, normal tissue tolerance limits, and field-specific toxicity management.

---

1. Biophysics & Radiobiology Foundations

Ionizing radiation deposits energy into target tissues through two primary mechanisms:

• Direct Action: Radiation directly ionizes target DNA molecules, breaking chemical bonds and causing single-strand (SSB) or double-strand DNA breaks (DSB). This mechanism dominates with high Linear Energy Transfer (LET) particulate radiation (e.g., alpha particles, protons).
• Indirect Action: Radiation interacts with intracellular water molecules (radiolysis), generating reactive oxygen species (ROS) such as hydroxyl free radicals ($ ext{OH}^ullet$). These free radicals subsequently react with DNA strands, causing structural damage. Indirect action accounts for approximately two-thirds of DNA damage induced by low-LET photon radiation (X-rays and gamma rays).

The 4 Rs of Radiobiology

The differential biological response between neoplastic tissue and surrounding normal tissue during fractionated radiation therapy is governed by the classic 4 Rs of Radiobiology:

---

2. Radiation Modalities & Delivery Technologies

Modern radiation oncology employs sophisticated treatment delivery platforms designed to maximize tumor control probability (TCP) while minimizing normal tissue complication probability (NTCP).

External Beam Radiation Therapy (EBRT)

• 3D Conformal Radiation Therapy (3D-CRT): Uses CT imaging to shape radiation beams matching the 3D contour of the tumor, reducing exposure to adjacent normal tissues.
• Intensity-Modulated Radiation Therapy (IMRT): Utilizes computer-controlled multileaf collimators (MLCs) to vary beam intensity dynamically across the treatment field, creating concave dose distributions around critical organs at risk (OARs).
• Volumetric Modulated Arc Therapy (VMAT): An advanced form of IMRT where radiation is delivered continuously as the linear accelerator rotates 360° around the patient, drastically reducing treatment delivery time.
• Stereotactic Body Radiation Therapy (SBRT / SABR): Delivers ablative, ultra-high radiation doses in 1 to 5 fractions to small, well-demarcated extracranial lesions (e.g., early-stage NSCLC, solitary liver or spine metastases).
• Stereotactic Radiosurgery (SRS): Single-fraction or hypofractionated high-dose radiation delivered specifically to intracranial targets (e.g., brain metastases, acoustic neuromas) using specialized gamma ray or linear accelerator frames.
• Proton Beam Therapy: Employs heavy charged particles (protons) that deposit minimal dose in entry tissues, release the majority of their energy at a precise depth (Bragg Peak), and deliver zero exit dose, dramatically sparing healthy tissues beyond the target.

Brachytherapy & Systemic Radionuclides

• Sealed Source Brachytherapy: Placement of radioactive sources (e.g., Iridium-192, Iodine-125, Cesium-137) directly within or adjacent to the tumor volume. Delivered as Low-Dose-Rate (LDR, continuous over days) or High-Dose-Rate (HDR, intense dose over minutes per session). Used extensively in cervical, prostate, and breast cancers.
• Unsealed Systemic Radionuclides: Systemically administered radiopharmaceuticals targeting specific tissue receptors (e.g., Iodine-131 for thyroid carcinoma; Radium-223 dichloride for bone-metastatic castrate-resistant prostate cancer; Lutetium-177 dotatate for somatostatin-receptor-positive NETs).

---

3. Dosing, Fractionation & Normal Tissue Tolerance

Radiation dosage is quantified in Grays (Gy), where 1 Gy represents 1 Joule of energy absorbed per kilogram of tissue ($1 ext{ Gy} = 100 ext{ cGy} = 100 ext{ rads}$).

Fractionation Schemes

• Standard Fractionation: 1.8 to 2.0 Gy per fraction, administered once daily, 5 days per week, over 5 to 7 weeks (total dose 50–74 Gy).
• Hyperfractionation: Smaller dose per fraction (<1.8 Gy) given twice daily to reduce late toxicities while escalating total dose.
• Hypofractionation: Larger dose per fraction (>2.0 Gy) given over fewer total fractions (e.g., SBRT regimens), shortening overall treatment duration.
• Accelerated Fractionation: Standard dose per fraction given twice daily to shorten overall treatment time and combat rapid tumor repopulation.

Critical Dose Limits for Normal Tissue Organs at Risk (OARs)

Exceeding cumulative organ tolerance thresholds significantly increases the risk of severe, irreversible late toxicities:

---

4. Anatomical Field Toxicities & Clinical Presentation

Radiation toxicities are classified based on onset timing and cell-turnover kinetics:

• Acute Toxicities: Manifest during treatment or within 90 days post-RT. Occur in rapidly proliferating epithelial and mucosal tissues (skin, gastrointestinal mucosa, bone marrow).
• Late Toxicities: Manifest >90 days to years post-RT. Occur in slow-turnover stromal tissues and vascular endothelium, causing microvascular obliteration, progressive endarteritis, tissue hypoxia, and fibrosis.

Field-Specific Toxicities

1. Head & Neck Field:
   • Acute: Grade 1–4 mucositis, dysgeusia, odynophagia, moist desquamation, acute sialadenitis.
   • Late: Permanent xerostomia, trismus, hypothyroidism, carotid artery stenosis, osteoradionecrosis (ORN) of the mandible (mandibular bone death secondary to microvascular thrombosis; requires hyperbaric oxygen and surgical debridement).
2. Thoracic Field:
   • Acute: Acute esophagitis (dysphagia, substernal burning), acute radiation pneumonitis (occurs 1–6 months post-RT; clinical triad of dry cough, low-grade fever, exertional dyspnea; chest CT demonstrates ground-glass infiltrates conforming strictly to the radiation port).
   • Late: Pulmonary fibrosis, radiation pericarditis, coronary artery disease, esophageal strictures.
3. Abdominal & Pelvic Field:
   • Acute: Nausea/vomiting, radiation enteritis (cramping, watery diarrhea), radiation proctitis (tenesmus, rectal bleeding), radiation cystitis (dysuria, frequency, hematuria).
   • Late: Chronic radiation enteritis (malabsorption, strictures, bowel obstruction, fistulae), pelvic insufficiency fractures, radiation-induced hemorrhagic cystitis, vaginal stenosis/fibrosis, infertility.
4. Central Nervous System Field:
   • Acute: Acute cerebral edema (headache, nausea, focal neurological deficits; managed with dexamethasone).
   • Subacute/Late: Somnolence syndrome (4–8 weeks post-WBRT), radiation necrosis (focal tissue mass mimicking tumor recurrence; treated with hyperbaric oxygen, steroids, or bevacizumab), neurocognitive decline.

---

5. APRN Toxicity Management Protocols

Comprehensive APRN assessment, patient education, and timely pharmacological intervention are vital to maintaining treatment compliance and quality of life.

Radiation Dermatitis Management

• Prevention: Wash skin gently with lukewarm water and mild, non-perfumed soap. Apply hydrophilic non-scented emollients (e.g., Aquaphor, calendula cream) twice daily. Crucial instruction: Do not apply topical products within 2 hours prior to radiation treatments to avoid bolus effects.
• Dry Desquamation (itchy, flaking skin): Apply topical hydrocortisone 1% cream or aloe vera gel.
• Moist Desquamation (painful, weeping, denuded skin): Cleanse with sterile saline. Apply non-adherent hydrocolloid or silver sulfadiazine dressings. Obtain wound cultures if purulent drainage or infection is suspected.

Mucositis & Xerostomia Interventions

• Cleanse oral cavity with normal saline or sodium bicarbonate rinses every 2–4 hours; avoid commercial alcohol-containing mouthwashes.
• Initiate topical analgesic solutions ("Magic Mouthwash" containing diphenhydramine, lidocaine, and aluminum/magnesium hydroxide $\pm$ nystatin).
• Administer systemic analgesics (opioids) for severe pain to maintain nutritional intake.
• For xerostomia: Recommend artificial saliva substitutes, frequent fluid sips, and sialagogues such as pilocarpine (5 mg PO TID) or cevimeline (30 mg PO TID) if residual salivary gland function exists.

Acute Radiation Pneumonitis Management Protocol

• Diagnostic Confirmation: Perform chest CT to rule out infection, PE, or disease progression. Confirm radiologic infiltrates matching the radiation port.
• Pharmacological Therapy: Initiate high-dose systemic corticosteroids immediately: Prednisone 1 mg/kg/day IV/PO (or equivalent). Maintain high dose until clinical symptoms improve (typically 2 weeks), followed by a slow, gradual taper over 6 to 8 weeks.
• Warning: Rapid steroid tapers frequently precipitate severe rebound radiation pneumonitis.